Clinical Trials Directory

Trials / Completed

CompletedNCT01565681

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

A Phase 1 Single Ascending Dose Study of ASKP1240 in Healthy Male and Female Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
109 (actual)
Sponsor
Astellas Pharma Global Development, Inc. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of ASKP1240 after a single intravenous dose at escalating dose levels in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGASP1240infusion
DRUGPlaceboinfusion

Timeline

Start date
2009-01-01
Primary completion
2009-12-01
Completion
2009-12-01
First posted
2012-03-29
Last updated
2012-12-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01565681. Inclusion in this directory is not an endorsement.

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects (NCT01565681) · Clinical Trials Directory